Department of Neurology

Dr. Michael Pranzatelli - Publications

ORIGINAL RESEARCH REPORTS (peer-reviewed journals):

1. Pranzatelli MR, Stumpf DA. The metabolic consequences of experimental intracranial hemorrhage. Neurology 35:1299-1303, 1985.

2. Pranzatelli MR, Rubin G, Snodgrass SR. Serotonin-lesion myoclonic syndromes. I. Neurochemical profile and S1 receptor binding. Brain Research 364:57-66, 1986.

3. Pranzatelli MR, Snodgrass SR. Serotonin-lesion myoclonic syndromes. II. Analysis of individual syndrome elements, locomotor activity, and behavioral correlations. Brain Research 364:67-76, 1986.

4. Pranzatelli MR, Snodgrass SR. Antimyoclonic properties of S-2 serotonin receptor antagonists in the rat. Neuropharmacology 25:5-12, 1986.

5. Pranzatelli MR, Snodgrass SR. Enhanced selective 5-HT depletions in the DHT rat model:
Denervation supersensitivity and recovery of function. Psychopharmacology 89:449-455, 1986.

6. Pranzatelli MR, Snodgrass SR. Motor habituation in the DHT model: Bin analysis of daytime and nocturnal locomotor activity. Pharmacology Biochemistry and Behavior 24:1679-1686, 1986.

7. Pranzatelli MR, Gantner C, Snodgrass SR. 3-Acetylpyridine lesions and four serotonergic
behavioral syndromes in the rat. Brain Research Bulletin 18:159-163, 1987.

8. Pranzatelli MR, Schultz L, Snodgrass SR. High-dose clonidine motor syndrome: Relationship to serotonin syndrome. Behavioral Brain Research 24:221-232, 1987.

9. Pranzatelli MR, Snodgrass SR. Harmala alkaloids and related B-carbolines: A myoclonic model and antimyoclonic drugs. Experimental Neurology 96:703-719, 1987.

10. Pranzatelli MR, Jappay E, Snodgrass SR. Effects of 5-HT receptor subtype-selective drugs on locomotor activity and motor habituation in the DHT adult rat model. Pharmacology Biochemistry and Behavior 27:497-504,1987.

11. Pranzatelli MR, Snodgrass SR. The guinea pig myoclonic model: Behavioral supersensitivity to 5-hydroxytryptophan induced by intracisternal 5,7-dihydroxytryptamine. European Journal of Pharmacology 143:237-242, 1987.

12. Pranzatelli MR. The comparative pharmacology of the behavioral syndromes induced by TRH and by 5-HT in the rat. General Pharmacology 19:205-211, 1988.

13. Pranzatelli MR, Dailey A, Markush S. The regulation of TRH and serotonin receptors: Chronic TRH and analog administration in the rat. Journal of Receptor Research 8:667-681, 1988.

14. Pranzatelli MR. Effect of chronic treatment with 5-hydroxytryptophan on cortical serotonin
receptors in the rat. Clinical Neuropharmacology 11:257-262, 1988.

15. Pranzatelli MR. Effect of antiepileptic and antimyoclonic drugs on serotonin receptors in vitro. Epilepsia 29:412-419, 1988.

16. Pranzatelli MR. In vivo and in vitro effects of adrenocorticotrophic hormone on serotonin receptors in neonatal rat brain. Developmental Pharmacology and Therapeutics 12:49-56, 1989.

17. Pranzatelli MR, Eng B. Chronic ACTH treatment: Influence on 5-HT2 receptors and behavioral supersensitivity induced by 5,7-dihydroxytryptamine lesions. Peptides 10:5-8, 1989.

18. Pranzatelli MR. Benzodiazepine-induced shaking behavior in the rat: Structure-activity and relation to serotonin and benzodiazepine receptors. Experimental Neurology 104:241-250, 1989.

19. Pranzatelli MR, Dollison AM, Hlibczuk V. Intracisternal 5,7-dihydroxytryptamine lesions in neonatal and adult rats: Comparison of response to 5-hydroxytryptophan. Developmental Neuroscience 11:205-211, 1989.

20. Chiriboga CA, Pranzatelli MR, De Vivo DC. Chronic ACTH treatment increases striatal dopamine D-2 receptor binding in developing rat brain. Brain Dev 11:197-200, 1989.

21. Pranzatelli MR, Huang Y, Dollison AM, Stanley M. Brainstem serotonergic hyperinnervation modifies behavioral supersensitivity to 5-hydroxytryptophan in the rat. Developmental Brain Research 50:89-99, 1989.

22. Pranzatelli MR, Balletti J. Identification of 5-HT1A recognition sites in human ganglioneuroblastoma. European Journal of Pharmacology 170:127-128, 1989.

23. Butler PD, Pranzatelli MR, Barkai AL. Regional central serotonin-2 receptor binding and
phosphoinositide turnover in rats with 5,7-dihydroxytryptamine lesions. Brain Research Bulletin 24:125-129,1990.

24. Pranzatelli MR. Evidence for involvement of 5-HT2 and 5-HT1C receptors in the behavioral effects of the 5-HT agonist 1 -(2,5-dimethoxy-4-iodophenylaminopropane (DOI). Neuroscience Letters 115:74-80, 1990.

25. Pranzatelli MR, Dollison AM, Huang Y-y. The functional significance of neonatal 5,7-dihydroxytryptamine lesions in the rats: Response to selective 5-HT1A and 5-HT 2,1C agonists. Brain Research Bulletin 24:747-753, 1990.

26. Pranzatelli MR. Antimyoclonic effect of MK-801: A possible role for NMDA receptors in
developmental myoclonus of the neonatal rat. Clinical Neuropharmacology 13:329-338, 1990.

27. Pranzatelli MR. Neonatal 5,7-DHT lesions upregulate [3H]mesulergine-labelled spinal 5-HT1C binding sites in the rat. Brain Research Bulletin 25:151-153, 1990.

28. Pranzatelli MR. The regulation of 5-HT2 receptors in rat frontal cortex: Studies with a putative selective agonist and an antagonist. Biochemical Pharmacology 42:1099-1105, 1991.

29. Pranzatelli MR, Pluchino RS. The relation of central 5-HT1A and 5-HT2 receptors: Low dose agonist-induced selective tolerance in the rat. Pharmacology Biochemistry and Behavior 39:407-413, 1991.

30. Pranzatelli MR, Dailey A, Levy M, Dollison A. Absence of tolerance to the excitatory effects of benzodiazepines: Clonazepam-evoked shaking behavior in the rat. Pharmacology Biochemistry and Behavior 39:1021-1024,1991.

31. Pranzatelli MR. Regional central serotonin receptor binding in rats treated chronically with high-dose 5-hydroxy-L-tryptophan. Experimental Brain Research 87:340-344, 1991.

32. Pranzatelli MR, Balletti J. Characterization of 5-hydroxytryptamine1A -like binding sites in human ganglioneuroblastoma. Neuroscience Letters 132:117-120, 1991.

33. Pranzatelli MR, Albin RL, Cohen BH. Acute dyskinesias in young asthmatics on theophylline. Pediatric Neurology 7(3):216-219, 1991.

34. Pranzatelli MR, Pavlakis SG, Gould RJ, De Vivo DC. Hypothalamic-midbrain dysregulation syndrome: Hypertension, hyperthermia, hyperventilation, and decerebration. Journal of Child Neurology 6(2):115-122,1991.

35. Pranzatelli MR, Tkach K. Regional glycine receptor binding in the p,p'-DDT myoclonic rat model. Archives of Toxicology 66:73-76, 1992.

36. Pranzatelli MR, Balletti J. Serotonin receptors in human neuroblastoma: A possible biologic tumor marker. Experimental Neurology 115:423-427, 1992.

37. Pranzatelli MR, Murthy JN Pluchino RS. Identification of spinal 5-HT1C binding sites in the rat: characterization of [3H]mesulergine binding. Journal of Pharmacology and Experimental Therapeutics 261:161-165, 1992.

38. Murthy JN, Pranzatelli MR. Brainstem 5-hydroxytryptamine1A binding sites are not down-regulated by agonists which induce tolerance in the rat. Journal of Receptor Research 12:287-297, 1992.

39. Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, Dilling LA, Elia J, Kruesi MJP, Lackner A, Larsen SA, Lee K, Leonard HL, Markey SP, Martin A, Milstein S, Mouradian MM, Pranzatelli MR, Quearry BJ, Salazar A, Smith M, Straus SE, Sunderland T, Swede SE, Tourtellotte WW. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurologic disease. Brain 115:1249-1273, 1992.

40. Trifiletti R, Pranzatelli MR. ACTH binds to [3H]MK-801-labelled rat hippocampal NMDA receptors. European Journal of Pharmacology 226:377-379, 1992.

41. Pranzatelli MR, Martens JN. Plasticity and ontogeny of the central 5-HT transporter: effect of neonatal 5,7-dihydroxytryptamine lesions in the rat. Developmental Brain Research 70:191-195, 1992.

42. Pranzatelli MR. Serotonin receptor ontogeny: effects of agonists in one day old rats. Pharmacology Biochemistry and Behavior 43:1273-1277, 1992.

43. Pranzatelli MR, Murthy JN, Tailor PT. Novel regulation of 5-hydroxytryptamine1C receptors: down-regulation induced both by 5-HT1C agonists and antagonists. European Journal of Pharmacology 244:1-5, 1993.

44. Pranzatelli MR. Regional differences in the ontogeny of 5-hydroxytryptamine1C binding sites in rat brain and spinal cord. Neuroscience Letters 149:9-11, 1993.

45. Pranzatelli MR, Tailor PT, Razi P. Brainstem serotonin receptors in the guinea pig: implications for myoclonus. Neuropharmacology 32:209-215, 1993.

46. Pranzatelli MR, Gregory CM. High and low affinity 5-HT2 and 5-HT1C binding sites: responses to neonatal 5,7-DHT lesions in rat brain. Cytobios 75:197-209, 1993.

47. Toro C, Pascual-Leone A, Deuschl G, Tate E, Pranzatelli MR, Hallett M. Cortical tremor, a common manifestation of cortical myoclonus. Neurology 43:2346-2352, 1993.

48. Pranzatelli MR, Kao PC, Tate ED, Chaves E, Chez M, Dobyns WE, Kang H, Rothner DA.
Autoantibodies to ACTH in opsoclonus-myoclonus. Neuropediatrics 24:131-133, 1993.

49. Pranzatelli MR, Tailor PT, Pluchino R, Gonzales W, Simmens S. DDT myoclonic/epileptic model: serotonin receptor binding and behavioral studies in the rat. Neurotoxicology 15(2):261-272, 1994.

50. Pranzatelli MR. Dissociation of the plasticity of 5-HT1A sites and 5-HT transporter sites.
Neurochemistry Research 19:311-315, 1994.

51. Pranzatelli MR, Durkin MM, Barkai AI. Quantitative autoradiography of 5-hydroxy- tryptamine binding sites in rats with neonatal 5,7-dihydroxytryptamine lesions. Developmental Brain Research 80:1-6, 1994.

52. Pranzatelli MR, Razi P. Drug-induced regulation of [125I]iodocyanopindolol-labelled 5-hydroxytryptamine1B receptors in the central nervous system. Neuropsychopharmacology 10:259-264,1994.

53. Pranzatelli MR, Galvan I. Ontogeny of [125I]iodocyanopindolol-labelled 5-hydroxytryptamine1B binding sites in the rat CNS. Neuroscience Letters 149:9-11, 1994.

54. Pranzatelli MR, Tailor PT. Modulation of brainstem 5-HT1C receptors by serotonergic drugs in the rat. General Pharmacology 25:1279-1284, 1994.

55. Pranzatelli MR, Mott S, Pavlakis S, Conry J, Tate E. The clinical spectrum of secondary parkinsonism in childhood: A reversible disorder. Pediatric Neurology 10:131-140, 1994.

56. Pranzatelli MR, Tate E, Baldwin M. Clinical responses to 5-hydroxy-L-tryptophan in chronic pediatric opsoclonus-myoclonus suggest biochemical heterogeneity: a double-blinded placebo crossover pilot study. Clinical Neuropharmacology 17:103-116, 1994.

57. Pranzatelli MR, Huang Y-y, Tate E, Stanley M, Noetzel MJ, Gospe SM, Banasiak K. Cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in the pediatric opsoclonus-myoclonus syndrome. Annals of Neurology 37:189-197, 1995.

58. Papero PH, Pranzatelli MR, Margolis CJ, Tate E, Glass P. Neurobehavioral and psychosocial functioning of children with opsoclonus-myoclonus syndrome. Developmental Medicine and Child Neurology 37:915-932, 1995.

59. Pranzatelli MR, Tate E, Huang Y, Haas R, Bodensteiner J, Ashwal S, Franz D. The neuropharmacology of progressive myoclonus epilepsy: response to 5-hydroxy-L-tryptophan.
Epilepsia 36:783-791, 1995.

60. Mott SH, Packer RJ, Vezina LG, Kapur S, Dinndorf PA, Conry JA, Pranzatelli MR, Quinones RR. Encephalopathy with parkinsonian features in children following bone marrow transplantations treated with high dose amphotericin B. Annals of Neurology 37:810-814, 1995.

61. Tate E, Ho H, Kim A, Pranzatelli MR. A sensitive and quantitative pediatric myoclonus evaluation scale. Journal of Neuroscience Nursing 27:287-292, 1995.

62. Pranzatelli MR, Galvan I, Tailor PT. Human brainstem serotonin receptors: characterization and implications for subcortical myoclonus. Clinical Neuropharmacology 19(6):507-514, 1996.

63. Pranzatelli MR, Durkin MM, Farmer M. Quantitative autoradiography of 5-hydroxytryptamine1B binding sites in rats with neonatal 5,7-dihydroxytryptamine lesions. International Journal of Developmental Neuroscience 14:621-629, 1996.

64. Pranzatelli MR, Tate E, Wheeler A. A controlled trial of 5-hydroxy-L-tryptophan for ataxia in progressive myoclonus epilepsy. Clinical Neurology and Neurosurgery 98(2):161-164, 1996.

65. Connolly AM, Pestronk A, Shobhna M, Pranzatelli MR, Noetzel MJ. Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues. Journal of Pediatrics 130:878-884, 1997.

66. Lafreniere RG, Rochefort DL, Chretien N, Rommens JM, Cochius JL, Kalviainen R, Nousiainen U, Patry G, Farrell K, Soderfeldt B, Federico A, Hale BR, Cossio OH, Sorensen T, Pouliot MA, Kmiec T, Uldall P, Janszky J, Pranzatelli MR, Andermann F, Andermann E, Rouleau GA. Unstable insertion in the 5’ flanking region of the cystatin B gene is the most common mutation in progressive myoclonus epilepsy type 1, EPM1. Nature Genetics 15:298-302, 1997.

67. Bespalova IN, Adkins S, Pranzatelli M, Burmeister M. Novel cystatin B mutation and diagnostic PCR assay in Unverricht-Lündborg (Baltic) progressive myoclonus epilepsy patient. American Journal of Medical Genetics (Neuropsychiatric Genetics) 74(5):467-471, 1997.

68. Bespalova IN, Pranzatelli M, Burmeister M. G to C transversion at a splice acceptor site causes exon skipping in the cystatin B gene. Mutation Research Genomics 382:67-74, 1997.

69. Pranzatelli MR, Hanin I, Tate E, Kindel G, Bergin A, Brown CM, Habersang P, Habersang R, Mack KJ, Rosenbaum B, Selby KA. Cerebrospinal fluid free choline in movement disorders of pediatric onset. European Journal of Pediatric Neurology 1:33-39, 1998.

70. Pranzatelli MR, Huang YY, Tate E, Goldstein DS, Holmes CS, Goldstein EM, Ketner K, Kinast M, Lange BM, Sanz A, Shevell MI, Stanford RE, Taff IP. Monoaminergic effects of high dose corticotropin in corticotropin-responsive pediatric opsoclonus-myoclonus. Movement Disorders 13:522-528, 1998.

71. Pranzatelli MR, Tate ED. Chloral hydrate for progressive myoclonus epilepsy: A new look at an old drug. Pediatric Neurology 25:385-389, 2001.

72. Pranzatelli MR, Tate ED, Galvan I, Wheeler A. Controlled pilot study of piracetam for pediatric opsoclonus-myoclonus. Clinical Neuropharmacology 24:352-357, 2001.

73. Pranzatelli MR, Tate ED, Kinsbourne M, Caviness VS, Mishrah B. Forty-one year follow-up of childhood-onset opsoclonus-myoclonus: cerebellar atrophy, multiphasic relapses, response to IVIG. Movement Disorders 17(6):1387-1390, 2002.

74. Pranzatelli MR, Tate ED, Wheeler A, Bass N, Gold AP, Griebel ML, Gumbinas M, Heydemann PT, Holt PJ, Jacob P, Kotagal S, Minarcik CJ, Schub HS. Screening for autoantibodies in children with opsoclonus-myoclonus-ataxia. Pediatric Neurology 27(5):384-387, 2002.

75. Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Moticka EJ, Franz DN, Nigro MA, Parke JT, Stumpf DA, Verhulst SJ. B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes. Neurology 62(9):1526-1532, 2004.

76. Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Verhulst SJ. CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity. Movement Disorders 19(7):770-777, 2004.

77. Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Lee ND, Fisher J, Jasty R. Immunophenotype of blood lymphocytes in neuroblastoma-associated opsoclonus-myoclonus. Journal of Pediatric Hematology/Oncology 26(11):718-723, 2004.

78. Pranzatelli MR, Hyland K, Tate ED, Arnold LA, Allison TJ, Soori GS. Evidence of cellular immune activation in children with opsoclonus-myoclonus: cerebrospinal fluid neopterin. Journal of Child Neurology 19:919-924, 2004.

79. Pranzatelli MR, Tate ED, Travelstead AL, Longee D. Immunologic and clinical response to rituximab in a child with opsoclonus-myoclonus syndrome. Pediatrics 115(1):e115-e119, 2005.

80. Tate ED, Allison TJ, Pranzatelli MR, Verhulst SJ. Neuroepidemiologic trends in 105 U.S. cases of pediatric opsoclonus-myoclonus. Journal of Pediatric Oncology Nursing 22(1):8-19, 2005.

81. Pranzatelli MR, Chun KY, Moxness M, Tate ED, Allison TJ. Cerebrospinal fluid ACTH and cortisol in opsoclonus-myoclonus: effect of therapy. Pediatric Neurology 33:121-126, 2005.

82. Pranzatelli MR, Tate ED, Dukart WS, Flint MJ, Hoffman MT, Oksa AE. Sleep disturbance and rage attacks in opsoclonus-myoclonus syndrome: response to trazodone. Journal of Pediatrics 147(3):372-378, 2005.

83. Pranzatelli MR, Tate ED, Travelstead AL, Barbosa J, Bergamini RA, Civitello L, Franz DN, Greffe BS, Hanson RD, Hurwitz C, Kalinyak KA, Kelfer H, Khakoo Y, Mantovani JF, Nicholson HS, Sanders JM, Wegner S. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. Journal of Pediatric Hematology Oncology, in press.

REVIEW ARTICLES (peer-reviewed journals):

84. Pranzatelli MR, Snodgrass SR. The pharmacology of myoclonus. Clinical Neuropharmacology 8: 99-130, 1985.

85. Pranzatelli MR, De Vivo DC. The pharmacology of Reye syndrome. Clinical Neuropharmacology 10: 96-125, 1987.

86. Pranzatelli MR. The neurobiology of opsoclonus-myoclonus. Clinical Neuropharmacology 15(3): 186-228, 1992.

87. Pranzatelli MR. Serotonin and human myoclonus: rationale for the use of serotonin receptor agonists and antagonists. Archives of Neurology 51: 605-617, 1994.

88. Pranzatelli MR. Putative neurotransmitter abnormalities in infantile spasms: CSF neurochemistry and response to drugs. Journal of Child Neurology 9: 119-129, 1994.

89. Pranzatelli MR. On the molecular mechanism of adrenocorticotrophic hormone: neurotransmitters and receptors. Experimental Neurology 125: 142-161, 1994.

90. Pranzatelli MR, Nadi NS. Mechanism of action of antiepileptic and antimyoclonic drugs. Advances in Neurology 67: 329-360, 1995

91. Pranzatelli MR. Update on pediatric movement disorders. Advances in Pediatrics 42: 415-463, 1995.

92. Pranzatelli MR. The immunopharmacology of the opsoclonus-myoclonus syndrome. Clinical Neuropharmacology 19:1-47, 1996.

93. Pranzatelli MR. Advances in the treatment of pediatric movement disorders. International Pediatrics 10: 250-259,1995.

94. Pranzatelli MR. Antidyskinetic drug therapy for pediatric movement disorders. Journal of Child Neurology 11:355-369, 1996.

95. Pranzatelli MR. The pharmacology of antimyoclonic drugs. Clinical Neuroscience 3:246-252, 1996.

96. Pranzatelli MR. Movement disorders in childhood. Pediatrics in Review 17:388-394, 1996.

97. Pranzatelli MR. Oral pharmacotherapy for the movement disorders of cerebral palsy. Journal of Child Neurology 11 (suppl 1) S13-S22, 1996.

98. Pranzatelli MR. Paraneoplastic syndromes: An unsolved murder. Neuroimmunology issue, Seminars in Pediatric Neurology 7(2):118-130, 2000.

99. Pranzatelli MR. Infantile spasms vs. myoclonus: Is there a connection? In: Epilepsy, infantile spasms, and developmental encephalopathy. International Review of Neurobiology 49: 285-314, 2002.

100. Pranzatelli MR. A forward look at the therapy of pediatric movement disorders. Seminars in Pediatric Neurology 10:103-110, 2003.

101. Pranzatelli MR. Myoclonus in childhood. Seminars in Pediatric Neurology 10:41-51, 2003.


102. Pranzatelli MR. The proposed role of neurotransmitter receptors in the pathophysiology of human myoclonic disorders. Medical Hypotheses 30: 55-60, 1989.

103. Pranzatelli MR, Pedley TA. Differential diagnoses in childhood. In: Dam M, Gram L (eds)
Comprehensive Epileptology - An International Perspective, Raven Press, 423-447, 1990.

104. Pranzatelli MR, De Vivo DC. Role of the central nervous system in blood pressure regulation. In: Loggie J (ed) Pediatric Hypertension, Chapter 4, Blackwell Scientific Publication, 52-63, 1991.

105. Pranzatelli MR. An approach to movement disorders of childhood. Pediatric Annals 22: 13-17, 1993.

106. Pranzatelli MR. Myoclonic disorders. Pediatric Annals 22: 33-37, 1993.

107. Pranzatelli MR. Miscellaneous movement disorders of childhood. Pediatric Annals 22: 65-68, 1993.

108. Pranzatelli MR. Autoimmunity: the missing link in neurobiology of CNS paraneoplastic syndromes. Advances in Neuroimmunology 3:12-17, 1996. 

109. Pranzatelli MR. Use of 5,6- and 5,7-dihydroxytryptamine to lesion serotonin neurons. In: Kostrzewa RM (ed) Highly selective neurotoxins: Basic and clinical applications. Humana Press, Inc., Totowa, NY, 1997.

110. Pranzatelli MR. Myoclonic disorders. I. Diagnosis and pharmacotherapy. Drugs of Today: Timely Topics in Medicine 33 (4):237-250, 1997.

111. Pranzatelli MR. Myoclonic Disorders. II. Antimyoclonic drug sites and mechanisms of action. Drugs of Today: Timely Topics in Medicine 33 (5):315-324,1997.

112. Pranzatelli MR. Serotonergic drugs and movement disorders in humans. Drugs of Today: Timely Topics in Medicine 33 (6):379-392, 1997.

113. Pranzatelli MR. Central neurological paraneoplastic syndromes. Part 1. Clinical features, pathophysiology, and immunopharmacology. Drugs of Today 34 (5):415-430, 1998.

114. Pranzatelli MR. Central neurological paraneoplastic syndromes. Part 2. Practical, theoretical, and mechanistic considerations of treatment with drugs and biologicals. Drugs of Today 34(6), 1998.

115. Pranzatelli MR. Peripheral neurological paraneoplastic syndromes. Drugs of Today 34(7):625-639, 1998.

116. Tate E, Pranzatelli MR. Unforgettable Faces: Through the Eyes of a Nurse Practitioner. Atheneum Press, 461 pp, 1999.

117. Pranzatelli MR. A new age of CNS drug delivery. Drug & Market Development 10 (4):129-136, 1999.

118. Pranzatelli MR. Innovations in drug delivery to the central nervous system. Drugs of Today 35(6):435-448, 1999.

119. Pranzatelli MR. The new appeal of nicotinic acetylcholine receptors. Drug & Market Development 10(10):346-352,1999.

120. Pranzatelli MR. Friendly Fire. Discover April 2000, p 35-36.

121. Pranzatelli MR. Tremor disorders in children. International Tremor Foundation Spring 2000 Newsletter. pp. 1-5.

122. Pranzatelli MR. Opsoclonus-myoclonus syndrome. In The NORD Guide to Rare Diseases. Lippincott, Williams & Wilkins, Philadelphia, PA, 2003.

123. Pranzatelli MR. Progressive myoclonus epilepsy. In The NORD Guide to Rare Diseases. Lippincott, Williams & Wilkins, Philadelphia, PA, 2003.

124. Pranzatelli, MR. An update on OMS and Neuroblastoma. NB Journal, Spring Issue, 2004.

125. Pranzatelli MR. Pathophysiology, neurophysiology, and pharmacology of human myoclonus. In LeDoux M (ed) Animal Models of Movement Disorders, Elsevier Inc: Amsterdam, pp 397-413, 2005.

126. Pranzatelli, MR. Opsoclonus-myoclonus syndrome: Diagnostic and therapeutic considerations. In Steinlin M, Kaufmann F, Fuhrer K, Strozzi S (eds) Aktuelle Neuropädiatrie 2004, Novartis Pharma Verlag, Nürnberg, pp 120-131, 2005.

127. Pranzatelli MR. Myoclonus. Treatment of Pediatric Neurologic Disorders. Singer HS, Kossoff EH, Hartman AL, Crawford TO. Taylor & Francis, Boca Raton, pp 151-159, 2005.

128. Kramer K, Pranzatelli MR. Management of neurologic complications. In Cheung N-K V, Cohn SL (eds) Neuroblastoma, Springer-Verlog, Berlin, pp 213-222, 2005.

129. Pranzatelli MR. Opsoclonus-myoclonus-ataxia. In Fernandez-Alvarez E, Arzimanoglou A, Tolosa E (eds) Pediatric Movement Disorders, John Libbey Eurotext: Montrouge, France, pp 120-136, 2005.

130. Blumkin L, Pranzatelli MR. Acquired ataxias, infectious and parainfectious. In Subramony SH and Durv A (eds) Ataxia Disorders I. Handbook of Clinical Neurology series, 3rd Edition, in press.


131. Pranzatelli MR, Snodgrass SR. Fenfluramine therapy for autism. Journal of Autism and Developmental Disorders [letter] 15:439-441,1985.

132. Pranzatelli MR. Hypothalamic-midbrain dysregulation syndrome. Child Neurology [letter] 7: 116-117, 1992.

133. Pranzatelli MR, Franz D, Tate ED, Martens JM. Buspirone in progressive myoclonus epilepsy. Journal of Neurology Neurosurgery and Psychiatry [letter] 56(1): 114-115, 1993.

134. Pranzatelli MR. Dyskinesia secondary to aminophylline. Pediatric Neurology [letter] 1993.

135. Tate ED, Pranzatelli MR. Baltic myoclonus and crohn's disease. Movement Disorders [letter] 8(2) 252-253,1993.

136. Pranzatelli MR. Neuroblastoma masquerading as benign childhood ataxia: An unrecognized medical emergency. The Journal of Emergency Medicine, 26(2), 2004.